Kore Private Wealth’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$423K Sell
5,956
-515
-8% -$37.4K 0.08% 148
2022
Q2
$498K Buy
6,471
+190
+3% +$14.5K 0.08% 162
2022
Q1
$459K Buy
6,281
+368
+6% +$24.7K 0.06% 180
2021
Q4
$369K Buy
5,913
+313
+6% +$18.4K 0.05% 214
2021
Q3
$331K Sell
5,600
-27
-0.5% -$1.78K 0.03% 309
2021
Q2
$376K Buy
5,627
+539
+11% +$35.1K 0.04% 272
2021
Q1
$321K Sell
5,088
-2,467
-33% -$153K 0.04% 259
2020
Q4
$469K Buy
7,555
+671
+10% +$41.3K 0.07% 175
2020
Q3
$415K Buy
6,884
+287
+4% +$17.3K 0.08% 156
2020
Q2
$387K Buy
6,597
+78
+1% +$4.67K 0.08% 151
2020
Q1
$363K Buy
6,519
+431
+7% +$26.3K 0.09% 143
2019
Q4
$391K Buy
6,088
+322
+6% +$18.4K 0.07% 166
2019
Q3
$292K Buy
5,766
+225
+4% +$10.6K 0.07% 177
2019
Q2
$251K Sell
5,541
-890
-14% -$41.5K 0.06% 188
2019
Q1
$307K Buy
6,431
+988
+18% +$49.2K 0.07% 158
2018
Q4
$283K Buy
+5,443
New +$292K 0.08% 163

Other funds holding BMY

Kore Private Wealth's BMY Position: Q3 2022 in Review

Kore Private Wealth reduced its Bristol-Myers Squibb (BMY) stake by 8% in Q3 2022, selling an estimated $37.4K and leaving 5,956 shares worth $423K. The position accounts for 0.08% of the portfolio, ranked #148.

Kore Private Wealth first reported a position in BMY in Q4 2018 and has held it in 16 quarters since. The position peaked at $498K in Q2 2022. 2,470 funds tracked by Wall St. Rank hold BMY as of Q3 2022.

  • Kore Private Wealth held 5,956 shares of Bristol-Myers Squibb worth $423K as of Q3 2022.
  • Kore Private Wealth sold 515 Bristol-Myers Squibb shares in Q3 2022, an estimated $37.4K.
  • Bristol-Myers Squibb made up 0.08% of Kore Private Wealth's portfolio in Q3 2022, its #148 holding.
  • Kore Private Wealth first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 16 quarters since.
  • Kore Private Wealth's Bristol-Myers Squibb position peaked at $498K in Q2 2022.
  • 2,470 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.

Based on Kore Private Wealth's 13F filing for Q3 2022, filed 14 Nov 2022.